These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22337532)

  • 1. Validity of eight integrated healthcare delivery organizations' administrative clinical data to capture breast cancer chemotherapy exposure.
    Delate T; Bowles EJ; Pardee R; Wellman RD; Habel LA; Yood MU; Nekhlyudov L; Goddard KA; Davis RL; McCarty CA; Onitilo AA; Feigelson HS; Freml J; Wagner E
    Cancer Epidemiol Biomarkers Prev; 2012 Apr; 21(4):673-80. PubMed ID: 22337532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.
    Bowles EJ; Wellman R; Feigelson HS; Onitilo AA; Freedman AN; Delate T; Allen LA; Nekhlyudov L; Goddard KA; Davis RL; Habel LA; Yood MU; McCarty C; Magid DJ; Wagner EH;
    J Natl Cancer Inst; 2012 Sep; 104(17):1293-305. PubMed ID: 22949432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of electronic data on chemotherapy and hormone therapy use in HMOs.
    Ritzwoller DP; Carroll N; Delate T; O'Keeffe-Rossetti M; Fishman PA; Loggers ET; Aiello Bowles EJ; Elston-Lafata J; Hornbrook MC
    Med Care; 2013 Oct; 51(10):e67-73. PubMed ID: 22531648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal use of anthracycline-free perioperative chemotherapy in HER2-positive breast cancer patients.
    Watanuki R; Hayashida T; Kawai Y; Kikuchi M; Nakashoji A; Yokoe T; Toyota T; Seki T; Takahashi M; Kitagawa Y
    Int J Clin Oncol; 2019 Jul; 24(7):807-814. PubMed ID: 30810890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic overview of chemotherapy effects in breast cancer.
    Bergh J; Jönsson PE; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):253-81. PubMed ID: 11441936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.
    Cadoo KA; Morris PG; Cowell EP; Patil S; Hudis CA; McArthur HL
    Clin Breast Cancer; 2016 Dec; 16(6):487-493. PubMed ID: 27622751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
    van Ramshorst MS; van der Voort A; van Werkhoven ED; Mandjes IA; Kemper I; Dezentjé VO; Oving IM; Honkoop AH; Tick LW; van de Wouw AJ; Mandigers CM; van Warmerdam LJ; Wesseling J; Vrancken Peeters MT; Linn SC; Sonke GS;
    Lancet Oncol; 2018 Dec; 19(12):1630-1640. PubMed ID: 30413379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-related quality of life in early breast cancer.
    Groenvold M
    Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience.
    Horiguchi J; Oyama T; Takata D; Rokutanda N; Nagaoka R; Odawara H; Tokiniwa H; Tozuka K; Kikuchi M; Sato A; Takeyoshi I
    Anticancer Res; 2011 Sep; 31(9):3041-6. PubMed ID: 21868556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and risk factors for congestive heart failure in patients with early breast cancer who received anthracycline and/or trastuzumab: a big data analysis of the Korean Health Insurance Review and Assessment service database.
    Choi JY; Cho EY; Choi YJ; Lee JH; Jung SP; Cho KR; Kim CY; Kim YH; Park KH
    Breast Cancer Res Treat; 2018 Aug; 171(1):181-188. PubMed ID: 29737474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment patterns in patients with advanced breast cancer who were exposed to an anthracycline, a taxane, and capecitabine: a descriptive report.
    Donato BM; Burns L; Willey V; Cohenuram M; Oliveria S; Yood MU
    Clin Ther; 2010 Mar; 32(3):546-54. PubMed ID: 20399992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statin Exposure and Risk of Heart Failure After Anthracycline- or Trastuzumab-Based Chemotherapy for Early Breast Cancer: A Propensity Score‒Matched Cohort Study.
    Abdel-Qadir H; Bobrowski D; Zhou L; Austin PC; Calvillo-Argüelles O; Amir E; Lee DS; Thavendiranathan P
    J Am Heart Assoc; 2021 Jan; 10(2):e018393. PubMed ID: 33401953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer.
    Arciniegas Calle MC; Sandhu NP; Xia H; Cha SS; Pellikka PA; Ye Z; Herrmann J; Villarraga HR
    BMC Cancer; 2018 Oct; 18(1):1037. PubMed ID: 30359235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy.
    Yardley DA; Peacock N; Daniel B; Anz B; Molthrop DC; Shroff SK; Young R; Jankov A; Vander Woude A; Shastry M; Pasek J; DeBusk LM; Hainsworth JD
    Breast Cancer Res Treat; 2020 Apr; 180(3):647-655. PubMed ID: 32060783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
    Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
    Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients.
    Dietrich D; Krispin M; Dietrich J; Fassbender A; Lewin J; Harbeck N; Schmitt M; Eppenberger-Castori S; Vuaroqueaux V; Spyratos F; Foekens JA; Lesche R; Martens JW
    BMC Cancer; 2010 Jun; 10():247. PubMed ID: 20515469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer.
    McArthur HL; Mahoney KM; Morris PG; Patil S; Jacks LM; Howard J; Norton L; Hudis CA
    Cancer; 2011 Dec; 117(24):5461-8. PubMed ID: 21681735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Risk of Heart Failure in Breast Cancer Patients After Adjuvant Chemotherapy With or Without Trastuzumab.
    Banke A; Fosbøl EL; Ewertz M; Videbæk L; Dahl JS; Poulsen MK; Cold S; Jensen MB; Gislason GH; Schou M; Møller JE
    JACC Heart Fail; 2019 Mar; 7(3):217-224. PubMed ID: 30819377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary Development and Evaluation of an Algorithm to Identify Breast Cancer Chemotherapy Toxicities Using Electronic Medical Records and Administrative Data.
    Mandelblatt JS; Huang K; Makgoeng SB; Luta G; Song JX; Tallarico M; Roh JM; Munneke JR; Houlston CA; McGuckin ME; Cai L; Clarke Hillyer G; Hershman DL; Neugut AI; Isaacs C; Kushi L
    J Oncol Pract; 2015 Jan; 11(1):e1-8. PubMed ID: 25161127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nrdp1 expression to predict clinical outcome and efficacy of adjuvant anthracyclines-based chemotherapy in breast cancer: A retrospective study.
    Jiao S; Liu W; Wu M; Peng C; Tang H; Xie X
    Cancer Biomark; 2015; 15(2):115-23. PubMed ID: 25519010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.